Testosterone Replacement with 1% Testosterone Gel and Priapism: No Definite Risk Relationship

Journal of Sexual Medicine

Volumn 10, Issue 4, 2013, Pages 1151-1161

  Burnett, Arthur L ^a   Kan Dobrosky, Natalia ^b   Miller, Michael G ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Hypogonadism; Priapism; Testosterone Gel; Testosterone Replacement Therapy

Indexed keywords

PLACEBO; SILDENAFIL; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HEMATURIA; HUMAN; HYPOGONADISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MONOTHERAPY; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; POLLAKISURIA; POSTMARKETING SURVEILLANCE; PRIAPISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SHOULDER PAIN; SIDE EFFECT; SKIN DISEASE; SYMPTOM; TESTIS DISEASE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; URINARY TRACT INFECTION; URINARY URGENCY; URINE RETENTION;

EID: 84875686202     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12059     Document Type: Article

References (48)

1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-731.
2. Institute of Medicine of the National Academies Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy, Board on Health Sciences Policy. Liverman C, Balzer D, eds. Testosterone and aging: Clinical research directions. Washington, DC: The National Academies Press; 2004.
3. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
4. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-598.
5. IMS National Prescription Audit. National Prescription Audit, June 2000-October 2009. IMS Health Inc.:Plymouth Meeting, PA; 2010.
6. Kaufman JM. Evolution of delivery systems for testosterone administration. Curr Sex Health Rep 2004;1:109-114.
7. Fortesta™ (testosterone) gel [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010.
8. Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011;8:2079-2089.
9. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R, the North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-2681.
10. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-4510.
11. Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and its disorders: Physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev 2001;22:342-388.
12. Morelli A, Filippi S, Zhang XH, Luconi M, Vignozzi L, Mancina R, Maggi M. Peripheral regulatory mechanisms in erection. Int J Androl 2005;28(suppl 2):23-27.
13. ® (testosterone gel) 1.62% [prescribing information]. North Chicago, IL: Abbott Laboratories; 2011.
14. ® (testosterone gel) 1% [prescribing information]. North Chicago, IL: Abbott Laboratories; 2010.
15. ® (testosterone) topical solution [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2010.
16. ® 1% (testosterone gel) [prescribing information]. Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2009.
17. Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: Pathogenesis, epidemiology, and management. J Sex Med 2010;7:476-500.
18. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID. American Urological Association guideline on the management of priapism. J Urol 2003;170:1318-1324.
19. Burnett AL. Sexual health outcomes improvement in sickle cell disease: A matter of health policy? J Sex Med 2012;9:104-113.
20. Burnett AL, Bivalacqua TJ. Priapism: New concepts in medical and surgical management. Urol Clin North Am 2011;38:185-194.
21. Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology 2001;57:970-972.
22. Cherian J, Rao AR, Thwaini A, Kapasi F, Shergill IS, Samman R. Medical and surgical management of priapism. Postgrad Med J 2006;82:89-94.
23. Zargooshi J. Priapism as a complication of high dose testosterone therapy in a man with hypogonadism. J Urol 2000;163:907.
24. Zelissen PM, Stricker BH. Severe priapism as a complication of testosterone substitution therapy. Am J Med 1988;85:273-274.
25. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-1457.
26. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-2575.
27. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging 2009;4:397-412.
28. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-2853.
29. Efficacy and safety of Androgel in the treatment of hypogonadal and low testosterone men with type 2 diabetes (NCT00141492). Bethesda, MD: http://clinicaltrials.gov, United States National Institutes of Health. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT00141492?term=00141492&rank=1 (accessed August 29, 2012).
30. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-663.
31. The Uppsala Monitoring Centre. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala, Sweden: The Uppsala Monitorin Centre (WHO Collaborating Centre for International Drug Monitoring); 2000:24.
32. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639-650.
33. Key LL, Myers MC, Kroovand RL, Kelly WS. Priapism following testosterone therapy for delayed puberty. Am J Dis Child 1989;143:1001-1002.
34. Madrid Garcia FJ, Diez Hernandez A, Madronero Cuevas C, Rivas Escudero JA, Delgado Gomez M, Garcia Alonso J. Priapism secondary to testosterone administration in the treatment of delayed puberty. [In Spanish] Arch Esp Urol 2001;54:703-705.
35. Ichioka K, Utsunomiya N, Kohei N, Ueda N, Inoue K, Terai A. Testosterone-induced priapism in Klinefelter syndrome. Urology 2006;67:622 e17-62218.
36. Shergill IS, Pranesh N, Hamid R, Arya M, Anjum I. Testosterone induced priapism in Kallmann's syndrome. J Urol 2003;169:1089.
37. Kulmala RV, Lehtonen TA, Tammela TL. Priapism, its incidence and seasonal distribution in Finland. Scand J Urol Nephrol 1995;29:93-96.
38. Sugihara T, Yasunaga H, Horiguchi H, Nishimatsu H, Matsuda S, Homma Y. Incidence and clinical features of priapism in Japan: 46 cases from the Japanese diagnosis procedure combination database 2006-2008. Int J Impot Res 2011;23:76-80.
39. Burnett AL. Pathophysiology of priapism: Dysregulatory erection physiology thesis. J Urol 2003;170:26-34.
40. Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL. New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 2012;9:79-87.
41. Viagra® (sildenafil citrate) tablets [prescribing information]. New York, NY: Pfizer, Inc.; 2010.
42. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284-293.
43. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol 1997;15:21-26.
44. Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: An 84-week phase III clinical trial. J Androl 2010;31:457-465.
45. Cobert BL. Cobert's manual of drug safety and pharmacovigilance. 2nd edition. Sudbury, MA: Jones and Bartlett Learning; 2012.
46. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998;20(suppl C):C40-44.
47. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf 2006;29:385-396.
48. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: A systematic review. Drug Saf 2009;32:19-31.